Table 1.

Influence of HDAC isoform expression and clinicopathologic variables on patient survival (N = 140)

CasesEventsMean survival (mo)SELog-rank test P
Age at diagnosis (y)
    ≤65711592.34.6
    >65692480.15.50.082
Dukes stage
    A32488.64.7
    B50588.63.1
    C482270.56.9
    D10823.28.1<0.001
Tumor stage
    T190
    T233783.35.2
    T3852387.94.7
    T413942.012.7<0.001
Nodal status
    N0851188.92.7
    N127981.38.6
    N2281944.78.7<0.001
Metastasis
    M01303191.53.6
    M110823.28.1<0.001
Grade
    G160
    G21143188.44.0
    G320873.110.90.157
HDAC1
    Negative891993.14.3
    Positive512066.05.20.022
HDAC2
    Negative598100.04.1
    Positive813176.85.30.001
HDAC3
    Negative38696.56.0
    Positive1023383.44.40.072
HDAC groups
    All negative221107.44.9
    Partially positive822189.84.6
    All positive361759.16.50.001